ADA-EASD diabetes guidance: Individualised treatment of hyperglycaemia

British Journal of Diabetes and Vascular Disease

Volumn 12, Issue 3, 2012, Pages 146-151

  Day, Caroline ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

ADA; consensus; EASD; hyperglycaemia; individualisation; type 2 diabetes

Indexed keywords

BROMOCRIPTINE; COLESEVELAM; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; MEGLITINIDE; METFORMIN; PRAMLINTIDE; ROSIGLITAZONE; SULFONYLUREA;

ARTICLE; DIABETES MELLITUS; DRUG TARGETING; HUMAN; HYPERGLYCEMIA; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE;

EID: 84862993782     PISSN: 14746514     EISSN: 17534305     Source Type: Journal    
DOI: 10.1177/1474651412450477     Document Type: Article

References (18)

1. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006 ; 49: 1711-21 (Pubitemid 44025023)
2. Bailey CJ, Day C. Thiazolidinediones today. Br J Diabetes Vasc Dis. 2001 ; 1: 7-13
3. EASD. Statement on withdrawal of Avandia (rosiglitazone) in Europe from the European Association for the Study of Diabetes (EASD). Sept2010. http://www.easd.org/easdwebfiles/annualmeeting/46thMeeting/Press/Other/ EASDAvandia.pdf (Accessed April 2012)
4. Bailey CJ, Day C, Campbell IW. A consensus algorithm for the treatment of hyperglycaemia in type 2 diabetes. Br J Diabetes Vasc Dis. 2006 ; 6: 147-8 (Pubitemid 44322462)
5. Nathan DM, Buse JB, Davidson , et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia. 2008 ; 51: 8-11 (Pubitemid 50004100)
6. Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia. 2009 ; 52: 17-30
7. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: a patient-centred approach. Position statement of the American Diabetes Assoication (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012 ; 55: 1577-96
8. Bailey CJ, Day C. Glucuretics to treat diabetes. Br J Diabetes Vasc Dis. 2010 ; 10: 178-84
9. Fonseca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010 ; 12: 384-92
10. Holt RIG, Barnett AH, Bailey CJ. Bromocriptine: old drug, new formulation and new indication. Diabetes Obes Metab. 2010 ; 12: 1048-57
11. Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Dev Therap. 2008 ; 2: 203-14
12. NICE. Liraglutide for the treatment of type 2 diabetes mellitus. TA203. October2010. http://www.nice.org.uk/nicemedia/live/13248/51313/51313.pdf. (Accessed April 2012)
13. Bergenstal RM, Bailey CJ, Kendall DM. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med. 2010 ; 123 (April). 374e9-374e18
14. Ismail-Beigi Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011 ; 154: 554-9
15. Wientjens WJHM. International charter of rights and responsibilities of people with diabetes. Br J Diabetes Vasc Dis. 2009 ; 9: 105-6
16. Bailey CJ, Kodack M. Patient adherence to medication requirements for therapy of type 2 diabetes. Int J Clin Pract. 2011 ; 65: 314-22
17. Emslie-Simith A, Dowall J, Morris A. The problem of polypharmacy in type 2 diabetes. Br J Diabetes Vasc Dis. 2003 ; 3: 54-56 (Pubitemid 37045610)
18. Bailey CJ, Day C. Anti-obesity fixed-dose combinations. Br J Diabetes Vasc Dis. 2012 ; 12: 2-5